![5000100-flag[1].jpg](https://evag-551d.kxcdn.com/cdn/farfuture/BIcd6Z7a1Uzb5LahErSGdoyqhDpItm5zvumsM9sBY60/mtime:1484756601/sites/default/files/5000100-flag%5B1%5D.jpg)
The best way to get viral material within the Scientific Community. Browse our viruses and derived products from the EVAg Portal.
A unique biological resource in the field of virology, readily available online. Users may benefit from special funding to access to products of interest, do not hesitate to apply.
An international group of 25 laboratories, including 16 EU member state institutions and 9 non-EU institutions, that represent an extensive range of virological disciplines.
An open entity aiming at developing synergies and complementary capabilities in such a way as to offer an improved access to researchers.
The quality of viruses and derived products is a key consideration when our products are to be made available. Improvements on quality process will be addressed during the project.
EVAg generates and distributes globally diagnostic materials and protocols in the event of epidemiological emergencies.
Focused on the creation of new tools, techniques and concepts to develop the infrastructure and to provide easier and less expensive access to virological materials.
A user-friendly web Portal with a continuously increasing number of viruses and derived products. Start here...
The EVAg initiative will increase competitiveness and, provides for a strong interaction with industry and a promising foundation for the innovation process between academia and industry.
- The European Commission -
The initiative has an important social impact with particular emphasis on human disease.
- The European Commission -
The quality of the installations cooperating in this consortium is excellent, representing some of the best available infrastructures across the EU and world-wide.
- The European Commission -
Call for action: increase in mortality and severity of #Chikungunya disease in Fortaleza, Brasil https://t.co/Nm25IBjPse
"Mitigating risk of imported YF cases seeding local transmission requires heightened surveillance globally" https://t.co/cJJAZrI1l6 https://t.co/Mrv6aEtaJq
Important meeting for @EVAg_EU : drafting the guidance document for #BenefitSharing ABS #NagoyaProtocol for collection holders. https://t.co/i3oYQttYkR
Congratulations to Michael Thomson from California State University, San Bernardino, the winner of our #ASV2017 #EVAg_eu raffle ! https://t.co/F4HoxiPNll
Dr Eva Harris giving a brilliant talk on #denguevirus and #zikavirus. Recent DENV infection protects against ZIKV #ASV2017 https://t.co/CRV0TbedoA
Find out what we did during #Zikavirus crisis, Sunday 25th 7pm, Viral #Epidemiology and Public Health session #ASV2017. Or visit our booth ! https://t.co/Mn2lYBciPE
Genome analysis of the #YellowFever 2017 Brasil strain by @fiocruz shows 8 mutations, 5 of them in the NS5. https://t.co/eypnY4EvSO https://t.co/oKXd5vGBNE
A one-day workshop was organised by our EVAg partner Animal and Plant Health Agency, APHA on the 15th of October, 2016. The aim of this workshop was t... read more
The next American Society of Tropical Medicine and Hygiene Annual Meeting will be held in November 13-17, 2016, in Atlanta, Georgia, USA.... read more
The World Health Organisation (WHO) has warned that Zika virus (ZIKV), a mosquito-borne virus that can infect humans, is likely to spread across the ... read more
We at Luminex were sincerely appreciative of your willingness to work with us during the development of our xMAP® MultiFLEX™ Zika RNA Assay. The materials from EVAg supported our FDA submission, which is now authorized for emergency use.
Sarah M. Dunlap, PhDDirector, Clinical Operations - Luminex Corporation
We received high quality products at no cost. It helped us a lot in achieving our project. Thank you!
John UserR & D - Laboratory
